Evozyne Names Senior Vice President of Research and Development

Sep 20, 2022

CHICAGO—September 20, 2022—Evozyne today announced Janne Kerovuo, PhD, as its senior vice president of research and development, a newly created position at the Chicago-based biology engineering company.

Founded by Paragon Biosciences in 2020, Evozyne creates novel proteins for therapeutics and sustainability solutions. Evozyne is developing technology platforms for gene optimization, antibody discovery, gene editing, carbon capture and battery technology.

Kerovuo was most recently chief science officer for California-based MycoWorks and has held a variety of leadership positions with companies including NewLeaf Symbiotics, Monsanto and Agradis during his 27-year career in biotech. He holds a PhD in biochemistry from the University of Helsinki.

“The most exciting parts of my scientific career have been in enzyme and gene discovery and protein design. I strongly believe that the Evozyne approach, using evolution-based design, represents the best opportunity to unlock transformational solutions,” Kerovuo said. “I look forward to meaningfully advancing the science to address some of the world’s most urgent needs.”

About Evozyne

Evozyne applies boundary-breaking biology that combines engineering and AI to develop transformative solutions in biotechnology and sustainability. Built by Paragon Biosciences, Evozyne created one of the most promising technologies to improve human life. By amplifying a protein’s function based on the rules of nature, Evozyne addresses complex, high-impact problems. For more information, visit

About Paragon Biosciences

Paragon is a life science innovator that creates, builds and funds life science companies in cell and gene therapy, biology engineering and advanced biotechnology. The company’s portfolio includes Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences and a consistent flow of early-stage companies. Paragon stands at the intersection of human need, life science, and company creation. For more information, visit

Media Contact:

Sheridan Chaney